Webcast ImageWebcast
Q2 2014 Incyte Corporation Earnings Conference Call (Live)
07/31/14 at 8:30 a.m. ET
Q2 2014 Incyte Corporation Earnings Conference Call
Thursday, July 31, 2014 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
INCY (Common)
Exchange   NASDAQ Change   + 1.06 (2.21%)
Price   $48.98 Volume  872,295
Last Trade   July 23, 2014 | 4:00 p.m. ET

Corporate Profile

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.

Recent News More >>
July 23, 2014Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera
Statistical significance not achieved for the primary endpoint of symptom control; positive trends in favor of ruxolitinib versus hydroxyurea observed RELIEF trial conducted in patients who were generally well-controlled on hydroxyurea but reporting continued disease-related symptoms, a different population than the pivotal Phase III RESPONSE trial RELIEF not included in, nor required for, polycythemia... 
Printer Friendly Version
July 14, 2014Incyte to Report Second Quarter 2014 Financial Results on July 31
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, July 31, 2014. The schedule for the press release and conference call is as follows: Q2 2014 Press Release: July 31, 2014 at 7:00 a.m. ET Q2 2014 Conference Call: July 31, 2014 at 8:30 a.m. ET ... 
Printer Friendly Version
July 08, 2014Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 8, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract revenue in the third quarter. Under the Incyte-Novartis Collaboration and License Agreement, Novartis received exclusive develo... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.